Rovalpituzumab tesirine

Drug Profile

Rovalpituzumab tesirine

Alternative Names: Rova-T; SC16LD6.5

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Stemcentrx
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DLL3 protein inhibitors; DNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 25 Jan 2017 AbbVie plans the phase III MERU trial for Small cell lung cancer (Late stage disease, Maintenance therapy) in USA (IV) (NCT03033511)
  • 01 Oct 2016 Phase-I clinical trials in Small cell lung cancer (Late-stage disease, First-line therapy, Monotherapy, Combination therapy) in USA (IV) (NCT02819999)
  • 01 Sep 2016 Stemcentrx initiates a phase I trial for Small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02874664)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top